Literature DB >> 24217676

Kidney cancer: Axitinib destined for second place?

Sarah Payton.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24217676     DOI： 10.1038/nrurol.2013.257

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  2 in total

1.  Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.

Authors:  Thomas E Hutson; Vladimir Lesovoy; Salman Al-Shukri; Viktor P Stus; Oleg N Lipatov; Angel H Bair; Brad Rosbrook; Connie Chen; Sinil Kim; Nicholas J Vogelzang
Journal:  Lancet Oncol       Date:  2013-10-25       Impact factor: 41.316

2.  Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial.

Authors:  Brian I Rini; Bohuslav Melichar; Takeshi Ueda; Viktor Grünwald; Mayer N Fishman; José A Arranz; Angel H Bair; Yazdi K Pithavala; Glen I Andrews; Dmitri Pavlov; Sinil Kim; Eric Jonasch
Journal:  Lancet Oncol       Date:  2013-10-18       Impact factor: 41.316
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.